- Home
- PKBK vs DSGN Comparison
PKBK vs DSGN Comparison
Compare PKBK & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKBK
- DSGN
- Stock Information
- Founded
- PKBK 1999
- DSGN 2017
- Country
- PKBK United States
- DSGN United States
- Employees
- PKBK N/A
- DSGN N/A
- Industry
- PKBK Major Banks
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- PKBK Finance
- DSGN Health Care
- Exchange
- PKBK Nasdaq
- DSGN Nasdaq
- Market Cap
- PKBK 249.7M
- DSGN 264.4M
- IPO Year
- PKBK N/A
- DSGN 2021
- Fundamental
- Price
- PKBK $23.01
- DSGN $5.69
- Analyst Decision
- PKBK
- DSGN Hold
- Analyst Count
- PKBK 0
- DSGN 3
- Target Price
- PKBK N/A
- DSGN $7.00
- AVG Volume (30 Days)
- PKBK 18.6K
- DSGN 128.3K
- Earning Date
- PKBK 10-18-2024
- DSGN 11-19-2024
- Dividend Yield
- PKBK 3.15%
- DSGN N/A
- EPS Growth
- PKBK N/A
- DSGN N/A
- EPS
- PKBK 2.34
- DSGN N/A
- Revenue
- PKBK $63,151,000.00
- DSGN N/A
- Revenue This Year
- PKBK N/A
- DSGN N/A
- Revenue Next Year
- PKBK N/A
- DSGN N/A
- P/E Ratio
- PKBK $9.96
- DSGN N/A
- Revenue Growth
- PKBK N/A
- DSGN N/A
- 52 Week Low
- PKBK $15.24
- DSGN $1.96
- 52 Week High
- PKBK $23.44
- DSGN $6.91
- Technical
- Relative Strength Index (RSI)
- PKBK 66.50
- DSGN 56.91
- Support Level
- PKBK $20.88
- DSGN $5.22
- Resistance Level
- PKBK $23.44
- DSGN $6.20
- Average True Range (ATR)
- PKBK 0.43
- DSGN 0.32
- MACD
- PKBK 0.17
- DSGN 0.03
- Stochastic Oscillator
- PKBK 74.10
- DSGN 62.61
About PKBK Parke Bancorp Inc.
Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.